Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
• Pathologically confirmed AJCC 7th/8th edition Stage IV adenocarcinoma or squamous cell carcinoma not eligible for curative treatment.
• Indication and suitability to receive palliative radiotherapy to the thorax (30Gy/10).
• Receiving or planned to receive nivolumab or pembrolizumab
• Prior history of systemic chemotherapy is permitted given a washout period of 4 weeks
• Age 18 or older
• ECOG Performance Status 0-2
• Life expectancy greater than 3 months
• Able and willing to provide informed consent
• Able to complete patient reported outcome questionnaires